

7 July 2011

'RESEARCH NEVER STOPS'

info@evotec.com | www.evotec.com

For further information,
please contact

Dr Werner Lanthaler
Chief Executive Officer
+49.(0)40.560 81-242
+49.(0)40.560 81-333 Fax
werner.lanthaler@evotec.com

Evotec AG
Schnackenburgallee 114
22525 Hamburg (Germany)

Evotec announces multi-target collaboration with UCB in neurodegenerative and neurological diseases

Hamburg, Germany –7 July 2011: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) today announced that it has entered into a three year integrated drug discovery collaboration with UCB to identify small molecule modulators of priority biological targets, selected by UCB, involved in CNS disorders.

As part of the collaboration, Evotec will apply their integrated drug discovery expertise and technologies to identify interesting small molecules against the selected targets. The molecules will be further optimised and progressed through lead optimization to a pre-clinical candidate.

Evotec will receive a fixed research funding fee over the term of collaboration and will be further rewarded on achieving the goals of the research collaboration with early stage discovery, preclinical and clinical milestones. In addition Evotec will receive royalties based on net sales of any approved drugs from the collaboration.

Dr Mario Polywka, Chief Operating Officer at Evotec stated: "We are extremely pleased that UCB selected Evotec to collaborate on this exciting Drug Discovery Collaboration. This integrated drug discovery deal showcases our CNS disease expertise coupled with our industry leading platform. We look forward to a fruitful collaboration with UCB."

No financial details are disclosed.

ABOUT EVOTEC AG

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation. Evotec has long-term discovery alliances with partners including Boehringer Ingelheim, CHDI, Genentech, Medimmune/Astra Zeneca, Novartis and Ono Pharmaceutical. In addition, the Company has existing development partnerships and product candidates both in clinical and preclinical development. These include partnerships with Boehringer Ingelheim, MedImmune and with Andromeda (Teva) in the field of diabetes. For additional information please go to www.evotec.com.

ABOUT UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company

focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8,000 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB).

FORWARD-LOOKING STATEMENTS — *Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this report. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.*